WFRF:(Gispert JD)
Sökning: WFRF:(Gispert JD) > (2020-2023) > Analysis of Psychol...
LIBRIS Formathandbok (Information om MARC21)
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 05126naa a2200517 4500 | |
| 001 | oai:prod.swepub.kib.ki.se:153669181 | |
| 003 | SwePub | |
| 008 | 240701s2023 | |||||||||||000 ||eng| | |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1536691812 URI |
| 024 | 7 | a https://doi.org/10.1001/jamanetworkopen.2022.509212 DOI |
| 040 | a (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Caprioglio, C4 aut |
| 245 | 1 0 | a Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline |
| 264 | c 2023-01-13 | |
| 264 | 1 | b American Medical Association (AMA),c 2023 |
| 520 | a Individuals who are amyloid-positive with subjective cognitive decline and clinical features increasing the likelihood of preclinical Alzheimer disease (SCD+) are at higher risk of developing dementia. Some individuals with SCD+ undergo amyloid-positron emission tomography (PET) as part of research studies and frequently wish to know their amyloid status; however, the disclosure of a positive amyloid-PET result might have psychological risks.ObjectiveTo assess the psychological outcomes of the amyloid-PET result disclosure in individuals with SCD+ and explore which variables are associated with a safer disclosure in individuals who are amyloid positive.Design, Setting, and ParticipantsThis prospective, multicenter study was conducted as part of The Amyloid Imaging to Prevent Alzheimer Disease Diagnostic and Patient Management Study (AMYPAD-DPMS) (recruitment period: from April 2018 to October 2020). The setting was 5 European memory clinics, and participants included patients with SCD+ who underwent amyloid-PET. Statistical analysis was performed from July to October 2022.ExposuresDisclosure of amyloid-PET result.Main Outcomes and MeasuresPsychological outcomes were defined as (1) disclosure related distress, assessed using the Impact of Event Scale–Revised (IES-R; scores of at least 33 indicate probable presence of posttraumatic stress disorder [PTSD]); and (2) anxiety and depression, assessed using the Hospital Anxiety and Depression scale (HADS; scores of at least 15 indicate probable presence of severe mood disorder symptoms).ResultsAfter disclosure, 27 patients with amyloid-positive SCD+ (median [IQR] age, 70 [66-74] years; gender: 14 men [52%]; median [IQR] education: 15 [13 to 17] years, median [IQR] Mini-Mental State Examination [MMSE] score, 29 [28 to 30]) had higher median (IQR) IES-R total score (10 [2 to 14] vs 0 [0 to 2]; P < .001), IES-R avoidance (0.00 [0.00 to 0.69] vs 0.00 [0.00 to 0.00]; P < .001), IES-R intrusions (0.50 [0.13 to 0.75] vs 0.00 [0.00 to 0.25]; P < .001), and IES-R hyperarousal (0.33 [0.00 to 0.67] vs 0.00 [0.00 to 0.00]; P < .001) scores than the 78 patients who were amyloid-negative (median [IQR], age, 67 [64 to 74] years, 45 men [58%], median [IQR] education: 15 [12 to 17] years, median [IQR] MMSE score: 29 [28 to 30]). There were no observed differences between amyloid-positive and amyloid-negative patients in the median (IQR) HADS Anxiety (–1.0 [–3.0 to 1.8] vs –2.0 [–4.8 to 1.0]; P = .06) and Depression (–1.0 [–2.0 to 0.0] vs –1.0 [–3.0 to 0.0]; P = .46) deltas (score after disclosure – scores at baseline). In patients with amyloid-positive SCD+, despite the small sample size, higher education was associated with lower disclosure-related distress (ρ = –0.43; P = .02) whereas the presence of study partner was associated with higher disclosure-related distress (W = 7.5; P = .03). No participants with amyloid-positive SCD+ showed probable presence of PTSD or severe anxiety or depression symptoms at follow-up.Conclusions and RelevanceThe disclosure of a positive amyloid-PET result to patients with SCD+ was associated with a bigger psychological change, yet such change did not reach the threshold for clinical concern. | |
| 700 | 1 | a Ribaldi, F4 aut |
| 700 | 1 | a Visser, LNCu Karolinska Institutet4 aut |
| 700 | 1 | a Minguillon, C4 aut |
| 700 | 1 | a Collij, LE4 aut |
| 700 | 1 | a Grau-Rivera, O4 aut |
| 700 | 1 | a Zeyen, P4 aut |
| 700 | 1 | a Molinuevo, JL4 aut |
| 700 | 1 | a Gispert, JD4 aut |
| 700 | 1 | a Garibotto, V4 aut |
| 700 | 1 | a Moro, C4 aut |
| 700 | 1 | a Walker, Z4 aut |
| 700 | 1 | a Edison, P4 aut |
| 700 | 1 | a Demonet, JF4 aut |
| 700 | 1 | a Barkhof, F4 aut |
| 700 | 1 | a Scheltens, P4 aut |
| 700 | 1 | a Alves, IL4 aut |
| 700 | 1 | a Gismondi, R4 aut |
| 700 | 1 | a Farrar, G4 aut |
| 700 | 1 | a Stephens, AW4 aut |
| 700 | 1 | a Jessen, F4 aut |
| 700 | 1 | a Frisoni, GB4 aut |
| 700 | 1 | a Altomare, D4 aut |
| 710 | 2 | a Karolinska Institutet4 org |
| 773 | 0 | t JAMA network opend : American Medical Association (AMA)g 6:1, s. e2250921-q 6:1<e2250921-x 2574-3805 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:153669181 |
| 856 | 4 8 | u https://doi.org/10.1001/jamanetworkopen.2022.50921 |
Hitta mer i SwePub
- Av författaren/redakt...
- Caprioglio, C
- Ribaldi, F
- Visser, LNC
- Minguillon, C
- Collij, LE
- Grau-Rivera, O
- visa fler...
- Zeyen, P
- Molinuevo, JL
- Gispert, JD
- Garibotto, V
- Moro, C
- Walker, Z
- Edison, P
- Demonet, JF
- Barkhof, F
- Scheltens, P
- Alves, IL
- Gismondi, R
- Farrar, G
- Stephens, AW
- Jessen, F
- Frisoni, GB
- Altomare, D
- visa färre...
- Artiklar i publikationen
- JAMA network ope ...
- Av lärosätet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
